Source comparison
How to Use Tesamorelin for HIV Lipodystrophy Protocol: Treatment Comparison
Before starting any VAT reduction protocol, understanding how tesamorelin compares to alternatives clarifies expectations. Tesamorelin 2mg daily GHRH analogue. Restores pulsatile GH secretion 15.2% (COSMIX trial) Daily subcutaneous injection Neutral to slightl
This comparison does not assign a generated winner or score.
- Before starting any VAT reduction protocol, understanding how tesamorelin compares to alternatives clarifies expectations.
- Tesamorelin 2mg daily
- GHRH analogue. Restores pulsatile GH secretion
- 15.2% (COSMIX trial)
- Daily subcutaneous injection
- Neutral to slightly negative during first 8 weeks; improves long-term as VAT decreases
- Gold standard for HIV lipodystrophy VAT reduction. Mechanism targets root cause (suppressed GH pulsatility) rather than symptom
- Growth Hormone 2–4 IU daily
- Direct GH replacement
- 12–18% (observational data)
- Negative. Sustained elevation drives insulin resistance and hyperglycaemia
- More potent but less physiological; risk of diabetes development limits use to patients with confirmed GH deficiency
- Metformin 1500–2000mg daily
- AMPK activation. Reduces hepatic glucose output
- 3–6% (indirect VAT effect)
- Oral twice daily
- Positive. Improves insulin sensitivity independent of VAT
- First-line for patients with insulin resistance; minimal direct lipolytic effect on VAT
- Dietary intervention (caloric deficit 500 kcal/day)
- Energy balance. Forces mobilisation of all fat depots
- 8–12% total fat (VAT + SAT combined)
- Continuous behaviour modification
- Positive if sustained; negative if yo-yo dieting occurs
- Essential adjunct to any protocol; alone, VAT reduction is slower and less targeted than with tesamorelin